Credit Suisse’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $159M | Sell |
165,324
-10,004
| -6% | -$9.51M | 0.15% | 115 |
|
|
2023
Q4 | $154M | Buy |
175,328
+6,224
| +4% | +$5.13M | 0.15% | 120 |
|
|
2023
Q3 | $139M | Buy |
169,104
+344
| +0.2% | +$270K | 0.14% | 130 |
|
|
2023
Q2 | $121M | Sell |
168,760
-1,006
| -0.6% | -$776K | 0.12% | 165 |
|
|
2023
Q1 | $139M | Sell |
169,766
-114
| -0.1% | -$86K | 0.14% | 144 |
|
|
2022
Q4 | $123M | Sell |
169,880
-56,730
| -25% | -$41.9M | 0.13% | 164 |
|
|
2022
Q3 | $156M | Sell |
226,610
-13,326
| -6% | -$8.39M | 0.17% | 109 |
|
|
2022
Q2 | $142M | Buy |
239,936
+32,125
| +15% | +$20.9M | 0.15% | 138 |
|
|
2022
Q1 | $145M | Buy |
207,811
+3,096
| +2% | +$1.96M | 0.12% | 162 |
|
|
2021
Q4 | $129M | Buy |
204,715
+7,775
| +4% | +$4.78M | 0.07% | 297 |
|
|
2021
Q3 | $119M | Sell |
196,940
-15,600
| -7% | -$9.68M | 0.07% | 304 |
|
|
2021
Q2 | $119M | Sell |
212,540
-360,913
| -63% | -$183M | 0.06% | 330 |
|
|
2021
Q1 | $271M | Buy |
573,453
+315,589
| +122% | +$154M | 0.14% | 133 |
|
|
2020
Q4 | $125M | Buy |
257,864
+674
| +0.3% | +$364K | 0.06% | 334 |
|
|
2020
Q3 | $144M | Sell |
257,190
-48,226
| -16% | -$29.2M | 0.09% | 247 |
|
|
2020
Q2 | $190M | Buy |
305,416
+109,049
| +56% | +$61.9M | 0.14% | 142 |
|
|
2020
Q1 | $95.9M | Sell |
196,367
-26,774
| -12% | -$11M | 0.08% | 234 |
|
|
2019
Q4 | $83.8M | Buy |
223,141
+44,674
| +25% | +$15M | 0.06% | 341 |
|
|
2019
Q3 | $49.5M | Sell |
178,467
-9,831
| -5% | -$2.91M | 0.04% | 458 |
|
|
2019
Q2 | $58.9M | Buy |
188,298
+59,786
| +47% | +$19.9M | 0.05% | 378 |
|
|
2019
Q1 | $52.8M | Sell |
128,512
-5,444
| -4% | -$2.24M | 0.05% | 407 |
|
|
2018
Q4 | $50M | Sell |
133,956
-27,872
| -17% | -$10.2M | 0.05% | 380 |
|
|
2018
Q3 | $65.4M | Buy |
161,828
+5,480
| +4% | +$2.09M | 0.06% | 335 |
|
|
2018
Q2 | $53.9M | Sell |
156,348
-1,801
| -1% | -$563K | 0.05% | 367 |
|
|
2018
Q1 | $54.5M | Sell |
158,149
-13,848
| -8% | -$4.82M | 0.05% | 384 |
|
|
2017
Q4 | $64.7M | Sell |
171,997
-32,312
| -16% | -$13.1M | 0.06% | 347 |
|
|
2017
Q3 | $91.4M | Buy |
204,309
+14,349
| +8% | +$6.83M | 0.09% | 232 |
|
|
2017
Q2 | $93.3M | Sell |
189,960
-24,752
| -12% | -$10.8M | 0.09% | 202 |
|
|
2017
Q1 | $83.2M | Buy |
214,712
+7,914
| +4% | +$2.93M | 0.08% | 260 |
|
|
2016
Q4 | $75.9M | Sell |
206,798
-52,111
| -20% | -$19.8M | 0.08% | 277 |
|
|
2016
Q3 | $104M | Buy |
258,909
+6,236
| +2% | +$2.5M | 0.1% | 202 |
|
|
2016
Q2 | $88.2M | Buy |
252,673
+16,234
| +7% | +$6.25M | 0.1% | 206 |
|
|
2016
Q1 | $85.2M | Sell |
236,439
-170,859
| -42% | -$70.4M | 0.1% | 207 |
|
|
2015
Q4 | $221M | Buy |
407,298
+146,257
| +56% | +$79.2M | 0.25% | 75 |
|
|
2015
Q3 | $121M | Sell |
261,041
-43,789
| -14% | -$23.5M | 0.15% | 137 |
|
|
2015
Q2 | $156M | Buy |
304,830
+40,632
| +15% | +$19.8M | 0.15% | 135 |
|
|
2015
Q1 | $119M | Sell |
264,198
-21,031
| -7% | -$8.91M | 0.12% | 175 |
|
|
2014
Q4 | $117M | Buy |
285,229
+29,142
| +11% | +$11.5M | 0.1% | 193 |
|
|
2014
Q3 | $92.3M | Buy |
256,087
+33,221
| +15% | +$11.1M | 0.08% | 260 |
|
|
2014
Q2 | $63M | Buy |
222,866
+11,516
| +5% | +$3.41M | 0.05% | 384 |
|
|
2014
Q1 | $63.5M | Sell |
211,350
-66,894
| -24% | -$20.6M | 0.06% | 331 |
|
|
2013
Q4 | $76.6M | Buy |
278,244
+57,548
| +26% | +$16.6M | 0.07% | 266 |
|
|
2013
Q3 | $69M | Sell |
220,696
-63,660
| -22% | -$16.7M | 0.07% | 259 |
|
|
2013
Q2 | $63.9M | Buy |
+284,356
| New | +$66.2M | 0.06% | 297 |
|
Other funds holding REGN
Credit Suisse's REGN Position: Q1 2024 in Review
Credit Suisse reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2024, selling an estimated $9.51M and leaving 165,324 shares worth $159M. The position accounts for 0.15% of the portfolio, ranked #115.
Credit Suisse first reported a position in REGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $271M in Q1 2021. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.
- Credit Suisse held 165,324 shares of Regeneron Pharmaceuticals worth $159M as of Q1 2024.
- Credit Suisse sold 10,004 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $9.51M.
- Regeneron Pharmaceuticals made up 0.15% of Credit Suisse's portfolio in Q1 2024, its #115 holding.
- Credit Suisse first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Regeneron Pharmaceuticals position peaked at $271M in Q1 2021.
- 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.